3 papers in the library · 109 citations · publishing 2009-2021
BMJ July 6, 2010 Simon D. Brandt, Harry Sumnall, Fiona Measham et al. 57 citations
After mephedrone was banned, internet vendors began selling substitute products. One widely promoted second-generation compound is Energy 1 (NRG-1), also called naphyrone (naphthylpyrovalerone, O-2482). This substance comes from a group of compounds originally documented in medicinal chemistry research.
Drugs and Alcohol Today April 13, 2009 Zoë Smith, Karenza Moore, Fiona Measham 34 citations
Ecstasy (MDMA) use in Britain has declined since 2001 according to the British Crime Survey, but a new form of MDMA powder or crystal has emerged as a 'premium' product, rebranded in response to user dissatisfaction with poor-quality pills. These changes occurred within a policy context that prioritized the drugs-crime relationship through coercive treatment of problem drug users and a focus on binge drinking, leading to a reduction in information, support, and treatment for ecstasy users since the mid-1990s Safer Dancing harm reduction model.
J Psychopharmacol December 13, 2021 Ben Sessa, Jacob S Aday, Steve O’Brien et al. 18 citations
An open-label study of 14 participants found that mood remained positive during the week after receiving MDMA in a clinical setting, contrary to the 'Blue Monday' crash reported by recreational users. Self-reported sleep quality improved at 3- and 6-month follow-ups compared to baseline. No participants used or desired to use illicit MDMA, and anecdotal reports were favorable. The findings suggest that negative after-effects previously associated with MDMA may stem from confounds such as illicit drug sourcing and recreational settings, rather than the drug itself.